The report analyzes and presents an overview of Biobetters market worldwide. "Biobetters or Biosuperiors are novel molecules derived from successful, approved biologic products that have been customized to enhance its overall efficacy. The primary characteristics targeted by these applicants include extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects. These molecules contain the same active ingredients such as antibodies to target the same protein, but feature different chemical or molecular properties than the original drug."
The report further discusses about applications, future prospects, and comparison of biobetters with originator drugs and biosimilars along with the strategic industry activities of major companies worldwide. In addition, major companies operating in the Biobetters arena worldwide including Amgen Inc., Cantab Biopharmaceuticals Ltd., Crucell NV, GreenCross Corporation, Hanmi Pharm Co. Ltd., Medgenics Inc., PharmaEssentia Corporation, Polytherics Ltd., SynBio LLC, Teva Pharmaceutical Industries Ltd., Xencor Inc., and others are profiled.